Photo of Dr. Hagop Kantarjian from obroncology.com
Sep 27, 2023, 18:06
Hagop Kantarjian: Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.
Quoting Hagop Kantarjian, Professor and Chair of the Department of Leukemia at MD Anderson Cancer Center, on X/Twitter:
“Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.”
For details click here.
Source: Hagop Kantarjian/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19